Last reviewed · How we verify
DOACs: Rivaroxaban, Dabigatran, Apixaban
DOACs: Rivaroxaban, Dabigatran, Apixaban is a Direct oral anticoagulant Small molecule drug developed by Bayer. It is currently in Phase 2 development for Atrial fibrillation for stroke prevention, Deep vein thrombosis and pulmonary embolism treatment and prevention.
Rivaroxaban, dabigatran, and apixaban are direct oral anticoagulants that inhibit Factor Xa or thrombin.
Rivaroxaban, dabigatran, and apixaban are direct oral anticoagulants that inhibit Factor Xa or thrombin. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis and pulmonary embolism treatment and prevention.
At a glance
| Generic name | DOACs: Rivaroxaban, Dabigatran, Apixaban |
|---|---|
| Sponsor | Bayer |
| Drug class | Direct oral anticoagulant |
| Target | Factor Xa or thrombin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
They work by directly inhibiting the coagulation cascade at the level of Factor Xa or thrombin, preventing the formation of blood clots. This is in contrast to traditional anticoagulants like warfarin, which work by inhibiting the production of vitamin K-dependent clotting factors.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis and pulmonary embolism treatment and prevention
Common side effects
- Gastrointestinal bleeding
- Hemorrhage
- Anemia
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial (PHASE3)
- DOAC in Unusual Site Venous Thrombosis
- DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial (EARLY_PHASE1)
- Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DOACs: Rivaroxaban, Dabigatran, Apixaban CI brief — competitive landscape report
- DOACs: Rivaroxaban, Dabigatran, Apixaban updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about DOACs: Rivaroxaban, Dabigatran, Apixaban
What is DOACs: Rivaroxaban, Dabigatran, Apixaban?
How does DOACs: Rivaroxaban, Dabigatran, Apixaban work?
What is DOACs: Rivaroxaban, Dabigatran, Apixaban used for?
Who makes DOACs: Rivaroxaban, Dabigatran, Apixaban?
What drug class is DOACs: Rivaroxaban, Dabigatran, Apixaban in?
What development phase is DOACs: Rivaroxaban, Dabigatran, Apixaban in?
What are the side effects of DOACs: Rivaroxaban, Dabigatran, Apixaban?
What does DOACs: Rivaroxaban, Dabigatran, Apixaban target?
Related
- Drug class: All Direct oral anticoagulant drugs
- Target: All drugs targeting Factor Xa or thrombin
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Indication: Drugs for Deep vein thrombosis and pulmonary embolism treatment and prevention
- Compare: DOACs: Rivaroxaban, Dabigatran, Apixaban vs similar drugs
- Pricing: DOACs: Rivaroxaban, Dabigatran, Apixaban cost, discount & access